DailyIQ
Last updatedUpdating…

KVUE·Kenvue Inc.

$17.81
-0.06 (-0.34%)
After Hours
High
$17.97
Open
$17.80
Market Cap
34.42B
52W High
$20.13
Low
$17.76
P. Close
$17.81
P/E
20.76
52W Low
$14.02
Fwd P/E
14.41
DailyIQ Est.
$19.51
Inst. Ownership
53.2%
Short Interest
3.73%
Days to Cover
3.4
Technical Score (1D)
14
SELL
News Sentiment
58
BULLISH
Kenvue’s board just approved a dividend hike, pushing the payout to a higher level than its parent, Johnson & Johnson, and giving the stock a yield that now sits above the industry average. The increase is backed by the company’s latest earnings guidance, which shows steady revenue growth from its consumer‑health portfolio and a robust cash‑flow outlook that should support the higher payout. For the next 1–10 trading days, this move signals to the market that Kenvue is confident in its cash‑generation capacity, potentially making it an attractive defensive play for income‑focused investors. The higher yield may also attract capital from dividend‑seeking funds that previously favored J&J, creating a short‑term inflow that could lift the share price. Watch for the upcoming earnings report in a few days, as any deviation from the guidance could quickly reverse the positive sentiment. Also keep an eye on regulatory developments, particularly any FDA or antitrust actions that could impact Kenvue’s product pipeline and, by extension, its dividend sustainability. If the company maintains its growth trajectory, the dividend hike could set a new benchmark for smaller pharmaceutical firms, prompting a broader revaluation of the sector.
Earnings Summary
Kenvue Inc. is a global consumer health company headquartered in Summit, New Jersey, offering a diversified portfolio across Self Care, Skin Health & Beauty, and Essential Health segments, with flagship brands such as Tylenol, Neutrogena, and Johnson’s. Operating in the consumer defensive household & personal products sector, the firm focuses on over‑the‑counter medications, personal care, and beauty solutions. In the most recent quarters, Kenvue’s revenue grew from $3.66 billion in Q4 2024 to $3.74 billion in Q1 2025 and $3.84 billion in Q2 2025, reflecting a steady 2–3% quarterly increase; EPS rose from $0.26 to $0.24 and then to $0.29, with each quarter beating analyst expectations (Q4 2024: $0.256 vs $0.26; Q1 2025: $0.227 vs $0.24; Q2 2025: $0.284 vs $0.29). The company maintained a pattern of EPS beats in the last three quarters, while revenue consistently outpaced estimates, indicating robust top‑line momentum amid modest margin pressure. Historically, Kenvue has delivered YoY revenue growth of roughly 5–6% over the past two years, with EPS growth lagging slightly due to rising raw‑material costs; the firm has consistently beat revenue estimates but has occasionally missed EPS targets, underscoring a focus on volume expansion. Recent news highlights a regulatory win in the National Advertising Division ruling that upholds Kenvue’s comparative efficacy claim for its hair‑loss line, potentially strengthening brand credibility and short‑term retail performance. The launch of the Zyrtec Allergen Shield Spray signals a strategic pivot toward drug‑free allergy solutions, which could broaden revenue streams and improve margins if priced at a premium. Investors should watch for early sales data on the new spray, guidance on cost‑control initiatives amid raw‑material cost pressures, and any updates on the pending Kimberly‑Clark acquisition, as these factors will shape the company’s near‑term profitability and capital allocation strategy.

EPS

EstBeatMiss
$0.21$0.24$0.28$0.31$0.34Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.29 - -
Q2'26$0.33$0.31-4.8%
Q1'26$0.31$0.32+4.5%
Q4'25$0.23$0.27+19.7%
Q3'25$0.26$0.28+5.7%
Q2'25$0.28$0.29+2.2%

Revenue

EstBeatMiss
$3.7B$3.8B$3.9B$4.0B$4.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.9B - -
Q2'26$4.0B$4.0B-2.2%
Q1'26$3.9B$3.9B-0.3%
Q4'25$3.8B$3.8B+0.7%
Q3'25 - $3.8B -
Q2'25 - $3.8B -

Market Data

KVUE Stock Snapshot

SELL14/100
$17.81+$0.00 (0.0%)
Market cap
34.42B
P/E ratio
20.8
Day range
$17.76 – $17.97
News sentiment
58/100 · Neutral
Analyst target
$19.50 (+9.5%)
Consensus
Hold · 22 analysts
52-week range+27.0% off low · -11.5% from high
$14.02$20.13
Price $17.81 DailyIQ Est. $19.51

The trend on KVUE is bearish, and the indicator set is confirming it rather than diverging. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What KVUE's own history says about today's numbers

Realized volatility (21d)
18.0% 20th pct
vs 200-day average
-0.9%
Up days (1y)
48%

Kenvue Inc. is currently running 18.0% annualised volatility over the last 21 sessions. Measured against KVUE's own 3 years of daily returns rather than a market-wide average, that is the 20th percentile unusually subdued by its own history, against a typical reading of 23.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

Price sits -0.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 55th percentile a somewhat wider gap than its own norm. Over the past year KVUE closed higher on 48% of sessions, and it is currently 1 session into a falling streak.

Overnight risk is measurable too: KVUE has opened more than 2% away from the prior close in 10 of 844 sessions (1.2% of the time), with the largest gaps running +4.0% and -3.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, KVUE moved an average of 0.8% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.1% and a largest of +1.8%.

All figures computed from 845 daily closes between 2023-05-04 and 2026-09-16, split-adjusted, recomputed daily. Percentiles are against KVUE's own 3-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of KVUE's sector?

Kenvue Inc. sits in the Consumer Staples sector, currently ranked 6th of 11 GICS sectors by relative-strength rotation score (improving).

Sector rank
#6 of 11
Sector state
Improving
Sector rotation score
60

Options Market

What is the options market pricing for KVUE?

CallsPuts

For Kenvue Inc.'s nearest expiry (2026-09-18, 0 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.29), with at-the-money implied volatility around 17.2%.

Put/call ratio (2026-09-18)
0.29
ATM implied volatility
17.2%
Total open interest
37,863

Analyst Rating Changes

Are analysts turning bullish or bearish on KVUE?

UBS most recently reiterated its rating on Kenvue Inc. to Neutral on Aug 11, 2026 with a price target of $19 (from $20). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBSNeutral
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 11, 2026UBSMaintainedNeutral$20 → $19
Jul 21, 2026BarclaysMaintainedEqual-Weight$18 → $19
Jul 16, 2026UBSMaintainedNeutral$18 → $20
Apr 15, 2026CitigroupMaintainedNeutral$20 → $19
Apr 14, 2026BarclaysMaintainedEqual-Weight$19 → $18
Apr 7, 2026UBSMaintainedNeutral$19 → $18
Mar 6, 2026BarclaysMaintainedEqual-Weight$18 → $19
Feb 18, 2026Canaccord GenuityMaintainedHold$17 → $18
Feb 18, 2026CitigroupMaintainedNeutral$18 → $20
Feb 18, 2026UBSMaintainedNeutral$17 → $19
Jan 30, 2026JefferiesDowngradeBuy → Hold$23 → $18
Nov 10, 2025BarclaysMaintainedEqual-Weight$17 → $18

KVUE Competitive Positioning

Kenvue Inc. (KVUE) is tracked alongside these names in Household & Personal Products on DailyIQ — ranked by market cap, with today's move alongside.